Completion of Enrolment and Treatment in the Phase 1 Study of MTX110 in the Treatment of Children…
10 July 2023 Biodexa Ltd(“Biodexa” or the “Company”) Completion of Enrolment and Treatment in the Phase 1 Study of MTX110 in theTreatment of Children with Newly Diagnosed Diffuse Midline Gliomas (DMGs) Biodexa Ltd (a wholly owned…